Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma

E. M. McKelvey, J. K. Luce, R. W. Talley, Evan M Hersh, J. S. Hewlett, T. E. Moon

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

One hundred thirty two patients with disseminated malignant melanoma were treated using a combination of BCNU, vincristine and imidazole carboxamide. A response rate of 23% was observed, while 16% had stable disease. The patients' median survival was 42 months from diagnosis and 5.3 months from the onset of treatment. The results are not significantly different from therapy with imidazole carboxamide alone. Patients on this study were observed to have significant reduction in the number of lymphocytes in their peripheral blood (mean 1800/mm 3, median 1550/mm 3). Patients with lymphopenia prior to the onset of therapy (86%) had a similar response rate but a shorter median survival (4.4 months vs. 7.8 months, P = .03) than patients with normal lymphocyte levels. The findings are compatible with recent observations on the importance of host immunocompetence in patients with malignant melanoma. Eosinophil levels were not closely correlated with response, although among patients with eosinophil counts of greater than 300/mm 3 (22%), a slightly higher response rate (29%) was observed (P = .13). Eosinophilia did not influence patient survival.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalCancer
Volume39
Issue number1
DOIs
StatePublished - 1977
Externally publishedYes

Fingerprint

Dacarbazine
Vincristine
Combination Drug Therapy
Melanoma
Eosinophils
Survival
Immunocompetence
Lymphopenia
Lymphocyte Count
Eosinophilia
Therapeutics
Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma. / McKelvey, E. M.; Luce, J. K.; Talley, R. W.; Hersh, Evan M; Hewlett, J. S.; Moon, T. E.

In: Cancer, Vol. 39, No. 1, 1977, p. 1-4.

Research output: Contribution to journalArticle

@article{ea4bd8ce1e0b419681f437a914e63636,
title = "Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma",
abstract = "One hundred thirty two patients with disseminated malignant melanoma were treated using a combination of BCNU, vincristine and imidazole carboxamide. A response rate of 23{\%} was observed, while 16{\%} had stable disease. The patients' median survival was 42 months from diagnosis and 5.3 months from the onset of treatment. The results are not significantly different from therapy with imidazole carboxamide alone. Patients on this study were observed to have significant reduction in the number of lymphocytes in their peripheral blood (mean 1800/mm 3, median 1550/mm 3). Patients with lymphopenia prior to the onset of therapy (86{\%}) had a similar response rate but a shorter median survival (4.4 months vs. 7.8 months, P = .03) than patients with normal lymphocyte levels. The findings are compatible with recent observations on the importance of host immunocompetence in patients with malignant melanoma. Eosinophil levels were not closely correlated with response, although among patients with eosinophil counts of greater than 300/mm 3 (22{\%}), a slightly higher response rate (29{\%}) was observed (P = .13). Eosinophilia did not influence patient survival.",
author = "McKelvey, {E. M.} and Luce, {J. K.} and Talley, {R. W.} and Hersh, {Evan M} and Hewlett, {J. S.} and Moon, {T. E.}",
year = "1977",
doi = "10.1002/1097-0142(197701)39:1<1::AID-CNCR2820390102>3.0.CO;2-R",
language = "English (US)",
volume = "39",
pages = "1--4",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma

AU - McKelvey, E. M.

AU - Luce, J. K.

AU - Talley, R. W.

AU - Hersh, Evan M

AU - Hewlett, J. S.

AU - Moon, T. E.

PY - 1977

Y1 - 1977

N2 - One hundred thirty two patients with disseminated malignant melanoma were treated using a combination of BCNU, vincristine and imidazole carboxamide. A response rate of 23% was observed, while 16% had stable disease. The patients' median survival was 42 months from diagnosis and 5.3 months from the onset of treatment. The results are not significantly different from therapy with imidazole carboxamide alone. Patients on this study were observed to have significant reduction in the number of lymphocytes in their peripheral blood (mean 1800/mm 3, median 1550/mm 3). Patients with lymphopenia prior to the onset of therapy (86%) had a similar response rate but a shorter median survival (4.4 months vs. 7.8 months, P = .03) than patients with normal lymphocyte levels. The findings are compatible with recent observations on the importance of host immunocompetence in patients with malignant melanoma. Eosinophil levels were not closely correlated with response, although among patients with eosinophil counts of greater than 300/mm 3 (22%), a slightly higher response rate (29%) was observed (P = .13). Eosinophilia did not influence patient survival.

AB - One hundred thirty two patients with disseminated malignant melanoma were treated using a combination of BCNU, vincristine and imidazole carboxamide. A response rate of 23% was observed, while 16% had stable disease. The patients' median survival was 42 months from diagnosis and 5.3 months from the onset of treatment. The results are not significantly different from therapy with imidazole carboxamide alone. Patients on this study were observed to have significant reduction in the number of lymphocytes in their peripheral blood (mean 1800/mm 3, median 1550/mm 3). Patients with lymphopenia prior to the onset of therapy (86%) had a similar response rate but a shorter median survival (4.4 months vs. 7.8 months, P = .03) than patients with normal lymphocyte levels. The findings are compatible with recent observations on the importance of host immunocompetence in patients with malignant melanoma. Eosinophil levels were not closely correlated with response, although among patients with eosinophil counts of greater than 300/mm 3 (22%), a slightly higher response rate (29%) was observed (P = .13). Eosinophilia did not influence patient survival.

UR - http://www.scopus.com/inward/record.url?scp=0017350352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017350352&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197701)39:1<1::AID-CNCR2820390102>3.0.CO;2-R

DO - 10.1002/1097-0142(197701)39:1<1::AID-CNCR2820390102>3.0.CO;2-R

M3 - Article

C2 - 832224

AN - SCOPUS:0017350352

VL - 39

SP - 1

EP - 4

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -